I wonder what the fastest drug approval was without a biomarker vs with a biomarker .... and I say PS Targeting begins a new wave of fast FDA approvals
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!